↓ Skip to main content

Potential synergy between tau aggregation inhibitors and tau chaperonemodulators

Overview of attention for article published in Alzheimer's Research & Therapy, September 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

news
1 news outlet

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
41 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Potential synergy between tau aggregation inhibitors and tau chaperonemodulators
Published in
Alzheimer's Research & Therapy, September 2013
DOI 10.1186/alzrt207
Pubmed ID
Authors

Laura J Blair, Bo Zhang, Chad A Dickey

Abstract

Tau is a soluble, microtubule-associated protein known to aberrantly form amyloid-positive aggregates. This pathology is characteristic for more than 15 neuropathies, the most common of which is Alzheimer's disease. Finding therapeutics to reverse or remove this non-native tau state is of great interest; however, at this time only one drug is entering phase III clinical trials for treating tauopathies. Generally, tau manipulation by therapeutics can either directly or indirectly alter tau aggregation and stability. Drugs that bind and change the conformation of tau itself are largely classified as aggregation inhibitors, while drugs that alter the activity of a tau-effector protein fall into several categories, such as kinase inhibitors, microtubule stabilizers, or chaperone modulators. Chaperone inhibitors that have proven effective in tau models include heat shock protein 90 inhibitors, heat shock protein 70 inhibitors and activators, as well as inducers of heat shock proteins. While many of these compounds can alter tau levels and/or aggregation states, it is possible that combining these approaches may produce the most optimal outcome. However, because many of these compounds have multiple off-target effects or poor blood-brain barrier permeability, the development of this synergistic therapeutic strategy presents significant challenges. This review will summarize many of the drugs that have been identified to alter tau biology, with special focus on therapeutics that prevent tau aggregation and regulate chaperone-mediated clearance of tau.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Unknown 40 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 8 20%
Student > Ph. D. Student 7 17%
Student > Master 5 12%
Researcher 4 10%
Professor > Associate Professor 3 7%
Other 3 7%
Unknown 11 27%
Readers by discipline Count As %
Agricultural and Biological Sciences 12 29%
Neuroscience 4 10%
Biochemistry, Genetics and Molecular Biology 4 10%
Chemistry 3 7%
Medicine and Dentistry 3 7%
Other 2 5%
Unknown 13 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 September 2014.
All research outputs
#4,836,164
of 25,374,917 outputs
Outputs from Alzheimer's Research & Therapy
#1,056
of 1,465 outputs
Outputs of similar age
#38,272
of 199,096 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#4
of 16 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,465 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.6. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 199,096 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.